Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06281028

SOLACEA-H in Heparin-sparing Haemodialysis

Led by GCS Ramsay Santé pour l'Enseignement et la Recherche · Updated on 2025-03-25

19

Participants Needed

1

Research Sites

40 weeks

Total Duration

On this page

Sponsors

G

GCS Ramsay Santé pour l'Enseignement et la Recherche

Lead Sponsor

E

Euraxi Pharma

Collaborating Sponsor

AI-Summary

What this Trial Is About

The aim of the study is to evaluate the efficacy of the SOLACEA-H dialyser, particularly in patients at high risk of haemorrhage, during post-dilution haemodiafiltration sessions with complete or partial heparin sparing. It will be compared with another dialyser (HYDROLINK-NVU)

CONDITIONS

Official Title

SOLACEA-H in Heparin-sparing Haemodialysis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • On haemodialysis for at least 3 months
  • Dialysis performed in a Ramsay-Santé group haemodialysis department
  • No active infection
  • Medically stable condition
  • Blood flow rate of at least 300 ml/min
  • Stable haemoglobin level above 10 g/dl within recommended norms for dialysis patients
  • Bipuncture access
  • No known allergy to SOLACEA-H or HYDROLINK-NVU
  • Willingness to comply with study procedures for the entire study duration
  • For women of childbearing age: use of effective contraception or negative pregnancy test
  • Member or beneficiary of a social security scheme
  • Informed consent signed by the patient
Not Eligible

You will not qualify if you...

  • Taking oral anticoagulants during the study period
  • Receiving dialysate during the study period
  • Medically unstable or fragile condition
  • Severe liver impairment
  • Hospitalized without consent
  • Participating in another clinical study concurrently
  • Under legal protection such as guardianship, curatorship, or deprived of liberty by judicial or administrative decision
  • Pregnant, breastfeeding, or recent childbirth
  • Unable to receive heparin
  • Known allergy to latex or phthalates

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hôpital Privé La Louvière

Lille, France, 59800

Actively Recruiting

Loading map...

Research Team

M

Maxime HOFFMANN, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

SOLACEA-H in Heparin-sparing Haemodialysis | DecenTrialz